AstraZeneca’s Enhertu was approved as the first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer following disease progression after one or more endocrine ...
Among patients with advanced PIK3CA-mutated, HR-positive/HER2-negative breast cancer, Itovebi-based treatment generated positive overall survival results.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback